The pharmaceutical and biotechnology industry is entering one of the most demanding stretches of its modern history: a $236 billion patent cliff, Medicare price negotiation with real teeth, AI rewriting the core scientific work, and wave after wave of restructuring, all at once. Most strategy decks describe these pressures. Far fewer describe the people expected to lead through them, or what those leaders will actually need to be capable of.
AIIR Consulting analyzed 251 executive coaching engagements with pharma and biotech leaders, comprising 700 development plans and 2,021 individual skill decisions, and compared them to our global cross-industry benchmark. The result is a rare, data-driven look at what pharma leaders are choosing to develop right now, where that focus is well placed, and where it is quietly creating risk for the decade ahead.